A Phase IB Study of Icapamespib in People with Persistent or Recurrent Malignant Glioma

Share

Full Title

A Phase 1b Dose Escalation/Dose Expansion Study of Icapamespib (PU-AD) in Patients with Recurrent Malignant Glioma

Purpose

The purpose of this study is to find the highest dose of the investigational drug icapamespib that can be given safely in people with malignant gliomas (brain tumors) that have come back or continued to grow despite treatment. Icapamespib targets and blocks the Hsp90 protein, which maintains and stabilizes cancer cells. Blocking this protein may prevent cancer survival and growth. Icapamespib is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have a malignant glioma (glioblastoma, gliosarcoma, or astrocytoma) which has come back or continued to grow despite treatment.
  • Prior treatment with Gliadel wafers (a treatment placed in the brain) is not permitted, nor is radiation therapy within 12 weeks of starting icapamespib treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information and to ask about eligibility for this study, please contact the office of Dr. Lauren Schaff at 212-610-0485.

Contact

 

 

 

Protocol

21-510

Phase

I/II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators